Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 9/20 | 0.33 |
| ▸ | CCNK | O75909 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6122857 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28735986 | 0.98 | KDM4E (0.38) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL28735985 | 0.98 | KDM4E (0.38) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL4761390 | 0.89 | — | — | |
| SCHEMBL14934875 | 0.89 | SMN1; SMN2 (0.36) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL15388091 | 0.89 | SMN1; SMN2 (0.36) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL1461782 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL29134334 | 0.85 | KDM4E (0.42) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL24429365 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 | |
| SCHEMBL15384122 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1IRAK4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207268-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-06-27 | — | — | US | claimed |
| EP-4313053-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2024-02-07 | — | — | EP | claimed |
| US-20230047732-A1 | PYRAZOLYLPYRIMIDINES AND USE THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2023-02-16 | — | — | US | claimed |
| WO-2022204220-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | BIOTHERYX, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| US-20240207268-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-06-27 | — | — | US | disclosed |
| EP-4313053-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| US-20230047732-A1 | PYRAZOLYLPYRIMIDINES AND USE THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2023-02-16 | — | — | US | disclosed |
| WO-2022204220-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | BIOTHERYX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-11-14 | — | — | US | disclosed |
| WO-2012101065-A2 | PYRIMIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101066-A1 | PYRIDINE BIARYL AMINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207268-A1 | PYRAZOLYLPYRIMIDINES FOR TREATING MALIGNANT SOLID TUMOR | VHL, TP53, TYMP | KDM4E 4012/4885ALDH1A1 1074/4885IRAK4 3619/4885 |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | KDM4E 528/4885ALDH1A1 2758/4885IRAK4 1388/4885 |
| US-20130303507-A1 | SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES | CDK9, CDK19, CDK3 | KDM4E 1438/4885ALDH1A1 2220/4885IRAK4 3277/4885 |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | CDK9, CDK19, CDKL1 | KDM4E 519/4885ALDH1A1 2840/4885IRAK4 1208/4885 |
| US-20230047732-A1 | PYRAZOLYLPYRIMIDINES AND USE THEREOF | MCL1, THPO, FLT3 | KDM4E 1921/4885ALDH1A1 101/4885IRAK4 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.